Immunological History in COVID-19

Project Title: Serological responses to human virome to identify immunological correlates and predictors of clinical outcomes

NIH Principal Investigator: Xin Wei Wang, Ph.D.
Deputy Chief, Laboratory of Human Carcinogenesis
Head, Liver Carcinogenesis Section, LHC

How does a person’s immunological history affect outcomes of COVID-19 infection?

The pattern and type of serological responses to human viruses represent a unique immunological host-specific signature that provides insight into the immunization history of the individual. In collaboration with Irini Sereti , M.D. (NIAID) and Andrea Lisco, M.D., Ph.D. (NIAID), the Laboratory of Human Carcinogenesis (LHC) of the National Cancer Institute (NCI) will use the VirScan technology to examine the humoral immunological signature of the human virome in COVID-19 patients. VirScan is a high-throughput methodology to comprehensively analyze antiviral antibodies using immunoprecipitation and massively parallel DNA sequencing of a bacteriophage library displaying proteome-wide coverage of peptides from all human viruses. They believe that this technique will identify immunological footprints predictive of different clinical outcomes of SARS-CoV-2 infection. The researchers will integrate the data from the other  COVID-19 research projects to provide a comprehensive analysis of the host-specific genetic and immunological characteristics predictive of COVID-19 clinical outcomes and to inform immunological treatment strategies.

Participating Groups

NIAID

Sample Requirements

20 µL of serum or plasma is required. Ideally, samples would be taken 1) upon hospital admission, 2) during hospitalization, 3) at discharge, and 4) after discharge.

Contact Information for Collaboration

If you are involved in the care of COVID-19 patients and are interested in collaborating on this project, please contact Xin Wei Wang, Ph.D.

Content last reviewed on